FRAGILE X SYNDROME (FXS)
Fully enrolled and not recruiting for Phase 2 Study
We are fully enrolled and not recruiting for a Phase 2 study to evaluate the safety, efficacy, tolerability, pharmacokinetics, and pharmacodynamics of SPG601 in adult men with Fragile X syndrome.
The FDA has approved the U.S. IND (IND 169282) and granted Orphan Drug Designation for SPG601 for the treatment of FXS.
Clinical Trial Sites are Fully Enrolled in the U.S.:
NCT06413537
Status: Active, not recruiting
Location
Cincinnati, Ohio at Cincinnati Children’s Hospital Medical Center
Contact: Dr. Craig Erickson craig@spinogenix.com
For additional information, visit ClinicalTrials.gov
